Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings, Inc.

Xeris Pharmaceuticals ( ($XERS) ) has issued an update. On July 15, 2026, Xeris Biopharma Holdings, Inc. completed privately negotiated exchange tr...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XERS	$7.98	+0.57%	369.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XERS	$7.98	+0.6%	369.50K
3
4
5
6

XERS

XERS

Get Xeris Biopharma Holdings, Inc. Data in Excel

Get Xeris Biopharma Holdings, Inc. Data in Excel